Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine in Locally Advanced and Metastatic Breast Cancer
NCT01126138Phase 3Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jul 2010
- Primary completion
- May 2015
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Vinorelbine + Capecitabine with Docetaxel + Capecitabine (2 arms). Primary endpoint: Progression-Free Survival up to 2 years. Status: unknown.
02
Drugs
capecitabinevinorelbinedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01126138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01126138.